Suppr超能文献

[肠道移植能否成为治疗肠衰竭的方法?]

[Can intestinal transplantation constitute treatment for intestinal failure?].

作者信息

Goulet O, Michel J L, Brousse N, Jan D, Ricour C, Revillon Y

机构信息

Service de Gastro-entérologie et Nutrition Pédiatriques, Hôpital Necker-Enfants-Malades, Paris.

出版信息

Ann Chir. 1999;53(5):412-21.

Abstract

The management of patients with intestinal failure has benefited from progress in parenteral nutrition (PN), especially home-based parental nutrition. Intestinal transplantation is now possible and in some conditions, constitutes the logical treatment option. Since 1985, more than 300 small-bowel grafts have been performed, involving the isolated small bowel with or without the colon (45%), the liver + small bowel (40%) or several organs (15%). 2/3 of recipients were under 20 years of age, and indications were short-bowel syndrome (64%), severe intractable diarrhea (13%), abdominal cancer (13%), or chronic intestinal pseudo-obstruction syndrome (8%). 51% of patients survived > 2 years after the graft. Patient and graft survival depends on the type of immunosuppression, i.e. Cyclosporine or FK 506. The results must be interpreted carefully as they represent the first experience in numerous centers using different immuno-suppressive protocols, without any randomization. The results from the largest of these centers more closely reflect the current situation and may exceed a 70% 2-year survival rate. Functional grafts lead to gastrointestinal autonomy (weaning of PN) while maintaining satisfactory nutritional status and normal growth in childhood. Intestinal transplantation is theoretically indicated for all patients permanently or persistently dependent on PN. However, as PN is generally well tolerated, even for long periods, each indication for transplantation must be carefully weighed up in terms of the iatrogenic risk and quality of life. When PN has reached its limits, especially those associated with vascular, infectious, hepatic or metabolic complications, intestinal transplantation must be undertaken. Transplantation of the small bowel alone remains the first option, as combined liver-small bowel grafting is only indicated in case of life-threatening progressive cirrhogenic liver disease.

摘要

肠衰竭患者的管理受益于肠外营养(PN)的进展,尤其是家庭肠外营养。现在肠移植已成为可能,在某些情况下,是合理的治疗选择。自1985年以来,已进行了300多例小肠移植,包括单独的小肠(带或不带结肠,占45%)、肝+小肠(占40%)或多个器官(占15%)。2/3的受者年龄在20岁以下,适应证包括短肠综合征(64%)、严重难治性腹泻(13%)、腹部癌症(13%)或慢性肠假性梗阻综合征(8%)。51%的患者移植后存活超过2年。患者和移植物的存活取决于免疫抑制类型,即环孢素或FK 506。由于这些结果代表了众多中心使用不同免疫抑制方案的首次经验,且未进行任何随机分组,因此必须谨慎解读。这些中心中规模最大的中心的结果更能反映当前情况,2年生存率可能超过70%。功能良好的移植物可实现胃肠道自主(停用PN),同时在儿童期维持令人满意的营养状况和正常生长。理论上,所有永久或持续依赖PN的患者都适合进行肠移植。然而,由于PN通常耐受性良好,即使长期使用也是如此,因此必须根据医源性风险和生活质量仔细权衡每一例移植适应证。当PN达到其极限,尤其是与血管、感染、肝脏或代谢并发症相关的极限时,必须进行肠移植。单独的小肠移植仍然是首选,因为联合肝小肠移植仅适用于危及生命的进行性肝硬化性肝病。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验